July 18, 2016
India's largest biopharma company Biocon (Bangalore, India) and partner FUJIFILM Pharma (Tokyo, Japan) launched the biosimilar Insulin Glargine in Japan last week.
The Insulin Glargine BS Injection Kit is "a ready-to-use, prefilled disposable pen with 3 ml of 100IU Insulin Glargine". Biocon and FUJIFILM Pharma aim to capture a significant share of the Japanese Glargine market of US$ 144 million, the second largest market outside of North America & Europe. According to the International Diabetes Federation, there were 7.2 million people with diabetes in Japan in 2015.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.